Oct. 12 (UPI) — The results of the ACTT-1 trial, which looked at the effectiveness of remdesivir as a treatment for COVID-19, have finally been published. So far the only drug that has been shown to reduce deaths from the disease has been dexamethasone, a steroid that suppresses the immune system through its anti-inflammatory effects. Steroids have a secondary effect on the disease — they don’t target the virus itself. Remdesivir, on the other hand, goes straight to the cause of the disease by inhibiting the virus.

The drug, which was developed by Gilead Sciences, was approved for use by the U.S. Food and Drug Administration under an “emergency use authorization” on May 1. It was recently used to treat President Donald Trump.

Gilead Sciences has claimed that the drug has significant benefits for patients — but robust data has been lacking until now. This makes the long-awaited results of